1. Home
  2. CLST vs LUNG Comparison

CLST vs LUNG Comparison

Compare CLST & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Catalyst Bancorp Inc.

CLST

Catalyst Bancorp Inc.

HOLD

Current Price

$15.03

Market Cap

54.6M

Sector

N/A

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$2.14

Market Cap

63.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLST
LUNG
Founded
1922
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
54.6M
63.6M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
CLST
LUNG
Price
$15.03
$2.14
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$6.81
AVG Volume (30 Days)
6.6K
1.1M
Earning Date
01-22-2026
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.60
N/A
Revenue
$11,340,000.00
$91,664,000.00
Revenue This Year
N/A
$9.21
Revenue Next Year
N/A
$5.03
P/E Ratio
$25.23
N/A
Revenue Growth
133.67
15.59
52 Week Low
$10.67
$1.31
52 Week High
$15.30
$9.37

Technical Indicators

Market Signals
Indicator
CLST
LUNG
Relative Strength Index (RSI) 68.54 65.71
Support Level $15.00 $1.57
Resistance Level $15.00 $1.74
Average True Range (ATR) 0.09 0.14
MACD -0.04 0.06
Stochastic Oscillator 95.56 100.00

Price Performance

Historical Comparison
CLST
LUNG

About CLST Catalyst Bancorp Inc.

Catalyst Bancorp Inc is a bank holding company. Through its subsidiary, which is a federally chartered community-oriented savings bank, it is engaged in attracting deposits from the general public and using those funds to invest in loans and securities. The sources of funds are customer deposits, repayments of loans, maturities of investments, and funds borrowed from outside sources, which are used for the origination of loans. It derives income principally from interest earned on loans and investment securities and, to a lesser extent, from fees received in connection with the origination of loans, service charges on deposit accounts, and other services.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: